Alkermes Moves Beyond EDT Merger; Bullish On Pipeline
This article was originally published in The Pink Sheet Daily
Newly-reconfigured Alkermes reported third quarter fiscal 2013 earnings, highlighting how far it’s come since merging with the drug delivery unit of Elan a year ago and the strides it’s made with its pipeline of late.
You may also be interested in...
As it continues its transformation into a drug development company, Alkermes says it is meeting its own expectations, but analysts are disappointed, at least in the short term.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.